Ingevity (NYSE:NGVT) Posts Earnings Results, Misses Expectations By $0.16 EPS

Ingevity (NYSE:NGVT) announced its quarterly earnings data on Wednesday. The company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.16), Zacks reports. Ingevity had a positive return on equity of 103.69% and a negative net margin of 5.14%.The business had revenue of $255.10 million during the quarter, compared to the consensus estimate of $257.27 million. During the same period in the prior year, the firm earned $0.95 EPS. The business’s revenue for the quarter was down 3.2% compared to the same quarter last year. Ingevity updated its FY 2026 guidance to 4.800-5.20 EPS.

Ingevity Stock Down 1.8%

NGVT stock opened at $69.87 on Thursday. Ingevity has a 1-year low of $28.49 and a 1-year high of $77.46. The business’s 50 day simple moving average is $66.75 and its 200 day simple moving average is $58.91. The company has a current ratio of 1.27, a quick ratio of 0.80 and a debt-to-equity ratio of 8.39. The firm has a market capitalization of $2.51 billion, a PE ratio of -38.39 and a beta of 1.34.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. BMO Capital Markets boosted their price target on shares of Ingevity from $64.00 to $70.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ingevity in a research report on Thursday, January 22nd. Wall Street Zen lowered Ingevity from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Zacks Research upgraded Ingevity to a “hold” rating in a research note on Tuesday, December 16th. Finally, Wells Fargo & Company upped their price objective on Ingevity from $60.00 to $65.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 28th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $67.50.

Hedge Funds Weigh In On Ingevity

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NGVT. Global Retirement Partners LLC acquired a new position in shares of Ingevity in the fourth quarter valued at $27,000. Meeder Asset Management Inc. bought a new stake in shares of Ingevity during the 4th quarter worth about $33,000. Kestra Advisory Services LLC bought a new stake in shares of Ingevity during the 4th quarter worth about $47,000. Geneos Wealth Management Inc. grew its stake in Ingevity by 85.8% in the 2nd quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock valued at $36,000 after buying an additional 387 shares during the last quarter. Finally, Headlands Technologies LLC bought a new position in Ingevity in the 2nd quarter valued at about $46,000. 91.59% of the stock is owned by institutional investors.

About Ingevity

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.